Search | Clinical Trials Finder

Conditions: Healthy Participants
Interventions: BMS-986196, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy Volunteer
Interventions: ABBV-1088, Placebo for ABBV-1088, Itraconazole (ITZ); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Anaheim, California • Grayslake, Illinois

Conditions: Renal Dialysis, Kidney Failure, Chronic
Interventions: MK-2060, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 3
States / cities: Orlando, Florida • Saint Paul, Minnesota • Knoxville, Tennessee

Conditions: Cystic Fibrosis
Interventions: VX-581, Placebo, D-IVA, TEZ; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 136 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy
Interventions: LY3509754, Placebo, Itraconazole, Midazolam; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Anaheim, California • Dallas, Texas

Conditions: Relapsing Multiple Sclerosis
Interventions: Ublituximab, Placebo; Biological · Drug
Lead sponsor: TG Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 41
States / cities: Birmingham, Alabama • Cullman, Alabama • Orange, California + 34 more

Conditions: Hypercholesterolemia
Interventions: CAT-2054, Placebo, CAT-2054-C, Atorvastatin; Drug
Lead sponsor: Catabasis Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Postbariatric Hypoglycemia
Interventions: MBX 1416 (Part A), MBX 1416 (Part B), Placebo, MBX 1416 (Part C); Drug
Lead sponsor: MBX Biosciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Familial Hypercholesterolemia - Heterozygous
Interventions: Inclisiran, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 9
States / cities: San Francisco, California • Washington D.C., District of Columbia • Boca Raton, Florida + 4 more

Conditions: Chronic Low-back Pain
Interventions: Spinal Manipulation Therapy (SMT), Naloxone, Placebo, Mindfulness Based Stress Reduction Therapy (MT); Other · Drug · Behavioral
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 2
States / cities: Chicago, Illinois • Nashville, Tennessee

Conditions: Healthy Volunteers
Interventions: TAK-988, TAK-988 Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Glendale, California • Millcreek, Utah

Conditions: Non-small Cell Lung Cancer
Interventions: canakinumab, canakinumab-matching placebo, pembrolizumab, carboplatin, cisplatin, paclitaxel, nab-paclitaxel, pemetrexed; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 673 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 4
States / cities: Long Beach, California • Los Angeles, California • Orlando, Florida + 1 more

Conditions: Overweight, Obesity
Interventions: NNC0662-0419, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Tempe, Arizona • Lincoln, Nebraska

Conditions: Healthy Volunteers
Interventions: ONO-2020, Placebo; Drug
Lead sponsor: Ono Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Cypress, California

Conditions: COVID-19
Interventions: ALG-097558, Dabigatran, Itraconazole, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Infections, Bacterial
Interventions: Gepotidacin RC Tablet, Gepotidacin HSWG Tablet, Gepotidacin Capsule; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Anaheim, California • Austin, Texas

Conditions: Healthy Volunteer Study
Interventions: SCO-120, matching placebo; Drug
Lead sponsor: Sun Pharma Advanced Research Company Limited; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Dilworth, Minnesota • Creve Coeur, Missouri

Conditions: Hepatitis C
Interventions: Pegylated Interferon Lambda (pegIFNλ), BMS-790052 (NS5A Inhibitor), Ribavirin (RBV), BMS-650032 (NS3 Protease Inhibitor), Pegylated Interferon Alfa-2a (pegIFNα-2a), Placebo (PBO) for BMS-650032 (Placebo for NS3 Protease Inhibitor), Placebo (PBO) for BMS-790052 (Placebo for NS5A Inhibitor), Placebo for Ribavirin (RBV); Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 13
States / cities: Phoenix, Arizona • Palm Springs, California • Aurora, Colorado + 10 more

Conditions: Ulcerative Colitis
Interventions: emvistegrast, Placebo-to-match emvistegrast; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 57
States / cities: Peoria, Arizona • Camarillo, California • Garden Grove, California + 46 more

Conditions: Obesity, Overweight
Interventions: NNC0487-0111, Placebo (NNC0487-0111); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 2
States / cities: San Antonio, Texas

Conditions: Healthy
Interventions: PF-07976016, Placebo, Midazolam; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 117 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Alzheimer's Disease
Interventions: LY2886721, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 20 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Beverly Hills, California

Conditions: Healthy Adults
Interventions: EDG-15400, Placebo; Drug
Lead sponsor: Edgewise Therapeutics, Inc.; Industry
Eligibility: 18 Years to 59 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Cystic Fibrosis
Interventions: PTI-428, Placebo; Drug
Lead sponsor: Proteostasis Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 20
States / cities: Stanford, California • Altamonte Springs, Florida • Gainesville, Florida + 16 more

Search by objective public record fields.

A Study to Determine the Safety, Drug Levels and Drug Effects of BMS-986196 and Food and Formulation Effects on Relative Absorption Healthy Participants

A Study to Assess Multiple Ascending Dose, Drug-Drug Interaction, and Asian Pharmacokinetic Study of ABBV-1088

Safety and Pharmacokinetics of MK-2060 in Older Participants With End-Stage Renal Disease on Hemodialysis (MK-2060-004)

Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants

A Study of LY3509754 in Healthy Non-Japanese and Japanese Participants

Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

A 2-Part, Phase 1, Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CAT-2054 in Healthy Subjects

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of MBX 1416 in Healthy Subjects

Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia

Efficacy of Spinal Manipulation Therapy or Mindfulness-based Reduction Therapy on Patients With Chronic Low Back Pain

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-988 in Healthy Participants

Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects

A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or Obesity

A Phase 1 Study of ONO-2020 in Healthy Participants

Phase 1 Study on Bioavailability, Food Effect, and Drug-Drug Interaction of ALG-097558 Tablets in Healthy Volunteers

To Assess Bioavailability, Food Effect and Pharmacokinetics of Gepotidacin Tablets: A Phase I, Single-Dose, 2 Part Study in Healthy Subjects.

Study to Determine Safety, Tolerability and Pharmacokinetics, of SCO-120 in Healthy Male and Post-menopausal Female Subjects

Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin

Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis

A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin

A Study to Learn How Different Amounts of the Study Medicine Called PF-07976016 Are Tolerated and Act in The Body in Healthy Adults

A Safety Study of LY2886721 Single Doses in Healthy Subjects

A Study of EDG-15400 in Healthy Adults

Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis